Sanjay Gandhi to Cardiovascular Diseases
This is a "connection" page, showing publications Sanjay Gandhi has written about Cardiovascular Diseases.
Connection Strength
0.935
-
Folse H, Sternhufvud C, Andy Schuetz C, Rengarajan B, Gandhi S. Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events. Clin Ther. 2014 Jan 01; 36(1):58-69.
Score: 0.282
-
Schuetz CA, van Herick A, Alperin P, Peskin B, Hsia J, Gandhi S. Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model. J Med Econ. 2012; 15(6):1118-29.
Score: 0.254
-
Gandhi S, Weinberg I, Margey R, Jaff MR. Comprehensive medical management of peripheral arterial disease. Prog Cardiovasc Dis. 2011 Jul-Aug; 54(1):2-13.
Score: 0.237
-
Ohsfeldt RL, Olsson AG, Jensen MM, Gandhi SK, Paulsson T. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial. J Med Econ. 2012; 15(1):125-33.
Score: 0.061
-
Ohsfeldt RL, Gandhi SK, Smolen LJ, Jensen MM, Fox KM, Gold A, Hsia J. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010; 13(3):428-37.
Score: 0.053
-
Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother. 2008 Apr; 9(5):669-76.
Score: 0.047